Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Brand-name drug

Premarin price, strengths & recalls

Brand of estrogens, conjugated (usp) (generic)

Pharmacies pay $208.17 for 30 tablets of Premarin 0.625 mg tablet this week, and from $208.02 to $452.22 across its 6 priced strengths and forms. The generic, estrogens, conjugated (usp), costs pharmacies from $158.91. It has 1 recall on record, none ongoing. Its official label last changed on June 3, 2026.

Brand
Pharmacies pay$208.17for 30 tablets of 0.625 mg tablet-0.1% in 4 weeks
Fair cash price
$249.90
Strengths
6
Makers
1
Updated
Nov 11

Premarin price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
0.3 mg tablet Brand$6.95$208.46 / 30 tabletsNo change+2.8%
0.45 mg tablet Brand$6.95$208.56 / 30 tablets-0.1%+2.9%
0.625 mg tablet Brand$6.94$208.17 / 30 tablets-0.1%+2.6%
0.9 mg tablet Brand$6.93$208.02 / 30 tabletsNo change+2.5%
1.25 mg tablet Brand$6.95$208.44 / 30 tablets-0.1%+2.7%
0.625 mg/mL vaginal cream Brand$15.07$452.22 / 30 gNo change+2.5%

The lowest cost per tablet is 0.9 mg tablet at $6.93. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Premarin vs generic estrogens, conjugated (usp)

Generics have the same active ingredient, strength and form, and FDA requires them to work the same way. What pharmacies pay for each, same quantity:

StrengthBrandGenericBrand costs
0.3 mg tablet$208.46$158.911.3x
0.45 mg tablet$208.56$160.441.3x
0.625 mg tablet$208.17$161.341.3x
0.9 mg tablet$208.02$167.041.2x
1.25 mg tablet$208.44$164.191.3x
GenericEstrogens, conjugated (USP) prices

Supply status: shortages & recalls

No shortage reportedChecked Nov 16, 2026
No ongoing recalls1 recall on record, latest Oct 5, 2016

Recalls

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for premarin? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedJune 3, 2026
Version37 of 30
EffectiveJun 4, 2026
Read the label

These highlights do not include all the information needed to use PREMARIN safely and effectively. See full prescribing information for PREMARIN. PREMARIN® (conjugated estrogens) tablets, for oral use Initial U.S. Approval: 1942

This drug has a boxed warning

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA

See full prescribing information for complete boxed warning.

Estrogen-Alone Therapy

•

There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens (5.2)

•

Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia (5.1, 5.3)

•

Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) (5.1)

•

The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older (5.3)

Estrogen Plus Progestin Therapy

•

Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia (5.1, 5.3)

•

The WHI estrogen plus progestin substudy reported increased risks of stroke, DVT, pulmonary embolism (PE), and myocardial infarction (MI) (5.1)

•

The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer (5.2)

•

The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older (5.3)

Estrogen-Alone Therapy

Endometrial Cancer

There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see Warnings and Precautions (5.2)].

Cardiovascular Disorders and Probable Dementia

Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1, 5.3), and Clinical Studies (14.5, 14.6)].

The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) (0.625 mg)-alone, relative to placebo [see Warnings and Precautions (5.1), and Clinical Studies (14.5)].

The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3), Use in Specific Populations (8.5), and Clinical Studies (14.6)].

In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens.

Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

Estrogen Plus Progestin Therapy

Cardiovascular Disorders and Probable Dementia

Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1, 5.3), and Clinical Studies (14.5, 14.6)].

The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo [see Warnings and Precautions (5.1), and Clinical Studies (14.5)].

The WHIMS estrogen plus progestin ancillary study of the WHI, reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3), Use in Specific Populations (8.5), and Clinical Studies (14.6)].

Breast Cancer

The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer [see Warnings and Precautions (5.2), and Clinical Studies (14.5)].

In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA, and other combinations and dosage forms of estrogens and progestins.

Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA004782 · Wyeth Pharms
First approved
May 8, 1942 (84 years ago)
Latest approved change
April 22, 2025
Approved label
PDF, Apr 25, 2025
Generic makers
2 approved generic applications on the market

Premarin questions

How much does premarin cost without insurance?

Pharmacies pay about $208.17 for 30 tablets of premarin 0.625 mg tablet ($6.94 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $249.90. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is there a generic for Premarin?

Yes: estrogens, conjugated (usp). Pharmacies pay from $158.91 for it. Compare estrogens, conjugated (usp) prices.

Is premarin in shortage?

No shortage is reported for premarin right now. We check the national shortage list every day.

Has premarin been recalled?

1 recall on record, none ongoing. Recalls name specific lots - check yours.

When did the premarin label last change?

The official label was last updated on June 3, 2026 (version 37). See what changed.

Talk about premarin

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.